July 26 (Bloomberg) -- Krka Group d.d., Slovenia’s biggest drugmaker, said first-half net income fell 3 percent to 90.1 million euros ($110 million).
Sales rose 7 percent in the period to 565.3 million euros from a year earlier, the Novo Mesto-based company said in regulatory filing today.
Krka’s full-year profit target is 170 million euros on sales of 1.13 billion euros, the company said in the statement.
To contact the reporter on this story: Gordana Filipovic in Belgrade at firstname.lastname@example.org
To contact the editor responsible for this story: James M. Gomez at email@example.com